

REMARKS

The application has been amended to provide priority information, to include sequence identifiers (i.e., SEQ ID NOs), and to present information incorporated by reference. Such amendments were previously filed on August 14, 2001, and June 24, 2002 in the parent application U.S. Patent Application Serial No. 09/576,062.

Applicants believe that no fees are necessitated by the present amendment. However, in the event that any fees are due or an amount is to be credited, Applicants thereby authorize the commission of patents to debit or credit Deposit Account No. 01-0535.

Respectfully submitted,



Mi K. Kim
Reg. No. 44, 830

AMYLIN PHARMACEUTICALS, INC.
9373 Towne Centre Drive
San Diego, CA 92121
Phone: (858) 552-2200
Facsimile: (858) 552-1936